There are 2789 resources available
971P - Is there a clinical benefit of nivolumab + ipilimumab in patients older than 75 years with advanced solid tumors?
Presenter: Thierry Landre
Session: ePoster Display
973P - A phase II study of PDR001 among patients with recurrent and/or metastatic esophageal squamous cell carcinoma: An interim analysis of KM-12
Presenter: Dong Ki Lee
Session: ePoster Display
974P - Genetic and molecular analysis of solid tumors with hyperprogressive disease after treatment with immunotherapy
Presenter: Daniel Trotier
Session: ePoster Display
975P - Impact of body mass index on the efficacy of immune checkpoint inhibitors in cancer
Presenter: Alejandro Rios Hoyo
Session: ePoster Display
976P - The 30-day mortality rate after first cycle of immunotherapy
Presenter: Osman Sutcuoglu
Session: ePoster Display
977P - Interim results of phase I dose escalation study of YBL-006: A novel anti-PD-1 monoclonal antibody in advanced solid tumors
Presenter: Keun-Wook Lee
Session: ePoster Display
979P - Efficacy of pembrolizumab with concomitant use of antibiotics
Presenter: Katharine Ng
Session: ePoster Display
980P - Phase Ib study of a liposomal formulation of eribulin (E7389-LF) + nivolumab (Nivo) in patients (pts) with advanced solid tumors
Presenter: Noboru Yamamoto
Session: ePoster Display
981P - Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
Presenter: Sarwan Bishnoi
Session: ePoster Display